154 related articles for article (PubMed ID: 1497648)
1. Rhamnose moiety of phosphoramidon is not required for in vivo inhibition of endothelin converting enzyme.
Pollock DM; Shiosaki K; Sullivan GM; Opgenorth TJ
Biochem Biophys Res Commun; 1992 Jul; 186(2):1146-50. PubMed ID: 1497648
[TBL] [Abstract][Full Text] [Related]
2. Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.
McMahon EG; Palomo MA; Brown MA; Bertenshaw SR; Carter JS
Am J Hypertens; 1993 Aug; 6(8):667-73. PubMed ID: 8217029
[TBL] [Abstract][Full Text] [Related]
3. Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats.
McMahon EG; Palomo MA; Moore WM
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S29-33. PubMed ID: 1725358
[TBL] [Abstract][Full Text] [Related]
4. Structure activity relationship of phosphoramidon derivatives for in vivo endothelin-converting-enzyme inhibition.
Bigaud M; Hauss B; Schalk C; Jauch MF; D'Orchymont H
Fundam Clin Pharmacol; 1994; 8(2):155-61. PubMed ID: 8020872
[TBL] [Abstract][Full Text] [Related]
5. Diuretic-natriuretic actions and pressor effects of big-endothelin (1-39) in phosphoramidon-treated rats.
Hoffman A; Haramati A; Dalal I; Shuranyi E; Winaver J
Proc Soc Exp Biol Med; 1994 Feb; 205(2):168-73. PubMed ID: 8108467
[TBL] [Abstract][Full Text] [Related]
6. Differences in potency of big endothelin-1-induced pressor action in rat isolated perfused mesenteric artery, hindquarter and lung.
Hisaki K; Matsumura Y; Fujita K; Maekawa H; Takaoka M; Morimoto S
Life Sci; 1994; 54(4):275-80. PubMed ID: 8289588
[TBL] [Abstract][Full Text] [Related]
7. Phosphoramidon inhibits the conversion of big ET-1 into ET-1 in the pithed rat and in isolated perfused rat kidneys.
Verbeuren TJ; Mennecier P; Merceron D; Simonet S; de Nanteuil G; Vincent M; Laubie M
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S81-4. PubMed ID: 7510006
[TBL] [Abstract][Full Text] [Related]
8. S 17162 is a novel selective inhibitor of big ET-1 responses in the rat.
Descombes JJ; Mennecier P; Versluys D; Barou V; de Nanteuil G; Laubie M; Verbeuren TJ
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S61-4. PubMed ID: 8587469
[TBL] [Abstract][Full Text] [Related]
9. Effects of metalloprotease inhibitors on smooth muscle endothelin-converting enzyme activity.
Balwierczak JL; Kukkola PJ; Savage P; Jeng AY
Biochem Pharmacol; 1995 Jan; 49(3):291-6. PubMed ID: 7857315
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-converting enzyme and its in vitro and in vivo inhibition.
Yano M; Okada K; Takada J; Hioki Y; Matsuyama K; Fukuroda T; Noguchi K; Nishikibe M; Ikemoto F
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S26-8. PubMed ID: 1725349
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of endothelins and big endothelins in ketamine/xylazine or urethane anesthetized rats.
Gratton JP; Maurice MC; Rae GA; D'Orléans-Juste P
Am J Hypertens; 1995 Nov; 8(11):1121-7. PubMed ID: 8554736
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic evidence for the specificity of the phosphoramidon-sensitive endothelin-converting enzyme for big endothelin-1.
Télémaque S; Gratton JP; Claing A; D'Orléans-Juste P
J Cardiovasc Pharmacol; 1993; 22 Suppl 8():S85-9. PubMed ID: 7510007
[TBL] [Abstract][Full Text] [Related]
13. Different pressor and bronchoconstrictor properties of human big-endothelin-1, 2 (1-38) and 3 in ketamine/xylazine-anaesthetized guinea-pigs.
Gratton JP; Rae GA; Claing A; Télémaque S; D'Orléans-Juste P
Br J Pharmacol; 1995 Feb; 114(3):720-6. PubMed ID: 7735698
[TBL] [Abstract][Full Text] [Related]
14. Phosphoramidon, a metalloproteinase inhibitor, suppresses the hypertensive effect of big endothelin-1.
Matsumura Y; Hisaki K; Takaoka M; Morimoto S
Eur J Pharmacol; 1990 Aug; 185(1):103-6. PubMed ID: 2226629
[TBL] [Abstract][Full Text] [Related]
15. Effects of phosphoramidon on endothelin-1 and big endothelin-1 production in human aortic endothelial cells.
Matsumura Y; Tsukahara Y; Kojima T; Murata S; Murakami A; Takada K; Takaoka M; Morimoto S
Biol Pharm Bull; 1995 Mar; 18(3):401-6. PubMed ID: 7550091
[TBL] [Abstract][Full Text] [Related]
16. Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1.
Trapani AJ; Balwierczak JL; Lappe RW; Stanton JL; Graybill SC; Hopkins MF; Savage P; Sperbeck DM; Jeng AY
Biochem Mol Biol Int; 1993 Dec; 31(5):861-7. PubMed ID: 8136704
[TBL] [Abstract][Full Text] [Related]
17. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme.
Hisaki K; Matsumura Y; Maekawa H; Fujita K; Takaoka M; Morimoto S
Am J Physiol; 1994 Feb; 266(2 Pt 2):H422-8. PubMed ID: 8141343
[TBL] [Abstract][Full Text] [Related]
18. Contraction to big endothelin-1, big endothelin-2 and big endothelin-3, and endothelin-converting enzyme inhibition in human isolated bronchi.
Yap EY; Battistini B; McKay KO
Br J Pharmacol; 2000 Jan; 129(1):170-6. PubMed ID: 10694217
[TBL] [Abstract][Full Text] [Related]
19. Human big endothelin releases prostacyclin in vivo and in vitro through a phosphoramidon-sensitive conversion to endothelin-1.
D'Orléans-Juste P; Lidbury PS; Telemaque S; Warner TD; Vane JR
J Cardiovasc Pharmacol; 1991; 17 Suppl 7():S251-5. PubMed ID: 1725347
[TBL] [Abstract][Full Text] [Related]
20. Different pharmacological profiles of big-endothelin-3 and big-endothelin-1 in vivo and in vitro.
D'Orléans-Juste P; Télémaque S; Claing A
Br J Pharmacol; 1991 Oct; 104(2):440-4. PubMed ID: 1797310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
